welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Optimum Insufflation Capacity in NMD
study id #: NCT01981915
condition: Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Chronic Respiratory Insufficiency
Patients with underlying neuromuscular disorder (NMD) often suffer from weakness in the inspiratory and expiratory muscles. Consequently they do not have the strength to generate the minimum flow of 160 to 300 liters/minute for an efficient cough function. The restricted cough function allows secretion to accumulate, which in turn causes narrowing of the airway lumen and makes ventilation of the neuromuscular patient even more difficult. The patient’s susceptibility to infection increases again and the vicious circle repeats itself. Severe secretion retention may even lead to ventilator failure. Effective secretion and cough management instead reduces the risk for stay in hospital. Therefore, secretion and cough management is a mandatory part of the therapeutic concept for treating patients with neuromuscular disease. The therapeutic efficacy of the Lung Insufflation Assist Maneuver(LIA) integrated in the ventilator VENTIlogic LS-plus manufactured by Weinmann GmbH+Co KG was studied in a pilot study carried out by the Dep. for Pediatric Pulmonology and Sleep Medicine at the University Hospital of Essen/Germany in cooperation with Research & Development at Weinmann GmbH &Co KG, Germany . The objective of the pilot study was to examine the therapeutic efficacy of LIAM as a cough support function in patients with neuromuscular disease and indications for mechanical ventilation. We hypothesized that i) a certain insufflation maneuver pressure may be optimal to achieve the highest individual peak cough flow and ii) that this pressure is below the pressure needed to achieve the maximum insufflation capacity. We define the lowest insufflation capacity at which the best individual PCF can be achieved as optimum insufflation capacity (OIC). The study was performed using two different techniques in order to demonstrate that findings are not dependent on maneuver details but are rather based on effects of maneuver pressure. The protocol was limited to techniques which do not require breath stacking: i) insufflation with an Intermittend Positive Pressure (IPPB) device and ii) with the VENTIlogic LS using LIAM.
intervention: IPPB, LIAM
mechanism of action: No pharmaceutical intervention
last updated: November 22, 2018
start date: January 2011
estimated completion: March 2013
phase of development: N/A
size / enrollment: 40
- insufflation capacity [ Time Frame: change of lung volume with the procedure; during hospital stay on average 3 days ]
Lung volume was measured during spontaneous breathing and after a lung insufflation assist maneuver.
- Peak cough flow [ Time Frame: change of peak cough flow with the procedure; during hospital stay on average 3 days ]
Peak cough flow was measured during spontaneous breathing and after a lung insufflation assist maneuver.
• neuromuscular disorder
• respiratory insufficiency
• use of home mechanical ventilation
• acute illness
• history of pneumothorax
Magnetic Resonance Imaging and Biomarkers for Muscular DystrophyThe purpose of this research study is to...
Biomechanical and Morphological Changes in Dystrophic MuscleThe loss of ability to walk in many chil...
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)This research study wants to learn more ...
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyThis is a multicenter, double blind, pla...
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory (PedsQLTM)There isn't specific Health related qual...
Open Label Extension Study of HT-100 in Patients With DMDThis study is designed to provide 6-mont...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
First Duchenne Drug Approved by the FDAhttps://www.youtube.com/watch?v=xQWfXKL1...
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidThis study investigates the hypothesis t...
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...